Abstract: The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.
Abstract: The present invention relates to a method for the production of 5-hydroxymethylfurfural (HMF), which converts a fructose-containing component using a catalytically active anolyte fraction, which has been produced by electrolysis of water, at a temperature of 90 to 200° C. and for obtaining an HMF-containing product mixture, wherein advantageously a high HMF selectivity is achieved with significantly lower by-product formation.
Type:
Grant
Filed:
May 28, 2019
Date of Patent:
July 11, 2023
Assignee:
SÜDZUCKER AG
Inventors:
Alireza Haji Begli, Christine Kröner, Waldemar Tschilingiri, Ralf Riemenschnitter, Kay Mantyk
Abstract: Novel Iridium complexes having three different bidentate ligands useful for phosphorescent emitters in OLEDs are disclosed. At least one of the three different bidentate ligands is a carbene ligand.
Type:
Grant
Filed:
July 12, 2021
Date of Patent:
July 4, 2023
Assignee:
UNIVERSAL DISPLAY CORPORATION
Inventors:
Jui-Yi Tsai, Chuanjun Xia, Chun Lin, Adrian U. Palacios, Enrique Oñate, Miguel A. Esteruelas, Pierre-Luc T. Boudreault, Sonia Bajo, Montserrat Oliván
Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
Type:
Grant
Filed:
April 28, 2021
Date of Patent:
July 4, 2023
Assignee:
JANSSEN PHARMACEUTICA NV
Inventors:
Steven Goldberg, Craig Woods, Timothy B. Rhorer, Connor Martin, Steven P. Meduna, Stefan McCarver, Alexander Valdes, Steven Loskot, Douglas Behenna, Alexander Raymond Rovira, Xiaohua Xue
Abstract: Disclosed are methods for ameliorating glycocalyx damage by administering a neuraminidase inhibitor. Also disclosed are methods for treating endothelial dysfunction and for improving flow mediated dilation.
Type:
Grant
Filed:
October 10, 2018
Date of Patent:
June 27, 2023
Assignee:
CURATORS OF THE UNIVERSITY OF MISSOURI UNIVERSITY
Inventors:
Luis A. Martinez-Lemus, Christopher A. Foote, Jaume Padilla
Abstract: Disclosed are compounds for medical uses, for example, compounds of formula Ia, wherein A1, A2, A3, A4, A5, A6, A7, R6, R7 and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Type:
Grant
Filed:
September 23, 2022
Date of Patent:
June 20, 2023
Assignee:
AbbVie Inc.
Inventors:
Ayman Allian, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Thomas B. Borchardt
Abstract: Provided herein are radiolabeled compounds useful for minimally invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for position emission tomography imaging of voltage gated sodium channels. Methods for prepared unlabeled and labeled compounds, and diagnostic methods using the compounds are also provided.
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
Type:
Grant
Filed:
June 17, 2021
Date of Patent:
June 13, 2023
Assignee:
Bristol-Myers Squibb Company
Inventors:
Peter W. Glunz, Vladimir Ladziata, Indawati De Lucca, George O. Tora, Tarun Kumar Maishal, Raghuram Tangirala, Kamalraj Thiyagarajan
Abstract: The subject invention provides methods for the chemical synthesis of racemic arsinothricin (D,L-AST), the novel organoarsenical antibiotic. One is by condensation of the 2-chloroethyl(methyl)arsinic acid with acetamidomalonate, and the second involves reduction of the N-acetyl-protected derivative of hydroxyarsinothricin (AST-OH) and subsequent methylation of the resulting sodium salt of trivalent arsenic intermediate with methyl iodide. The enzyme AST N-acetyltransferase (ArsN1) was utilized to purify L-AST from racemic AST. This expedient chemical synthesis of AST provides a source of this novel antibiotic for future drug development.
Type:
Grant
Filed:
December 5, 2022
Date of Patent:
June 6, 2023
Assignee:
The Florida International University Board of Trustees
Inventors:
Barry P. Rosen, Masafumi Yoshinaga, Stanislaw F. Wnuk, Md Abu Hasan Howlader, Sk Md Sazzad Hossain Suzol
Abstract: An object of the present invention is to provide a drug and a method which suppress progress of disease in which the amount of amyloid ? protein in the brain is increased, such as Alzheimer's disease. 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of reducing the amount of amyloid ? protein in the brain parenchyma, and thus is effective as an agent for reducing the amount of amyloid ? protein in the brain. Disease in which the amount of amyloid ? protein in the brain is increased, such as Alzheimer's disease, can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
Abstract: Silicon-based tetrahydrocannabinol derivatives and methods for their synthesis are provided, in which the derivatives contain a tetrahydrocannabinol molecule and at least one silicon-based group containing Si—O—Si bonds. The derivatives are useful in topical and dermatological compositions, have potential beneficial topical properties, and enhance solubility and compatibility in topical and dermatological formulations containing the silicon-based materials.
Type:
Grant
Filed:
December 10, 2020
Date of Patent:
June 6, 2023
Assignee:
GELEST, INC.
Inventors:
Barry C. Arkles, Taewoo Min, Jonathan D. Goff
Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
Type:
Grant
Filed:
July 8, 2019
Date of Patent:
June 6, 2023
Assignee:
Arch Biopartners, Inc.
Inventors:
Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing Sze Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
Abstract: The present invention relates to a method for increasing the blood-brain barrier permeability, and more particularly, to a method for increasing the blood-brain barrier permeability, the method including: (S1) a step of delivering a nanogenerator carrying a nitric oxide (NO) donor to a site adjacent to the blood-brain barrier; (S2) a step of delivering a first triggering stimulus to an area where the nanogenerator has been delivered so as to release nitric oxide from the nanogenerator; and (S3) a step of allowing the released nitric oxide to activate matrix metallopeptidase-9 (MMP-9) and inducing the activated MMP-9 to weaken the tight junction between a cerebrovascular endothelial cell and another cerebrovascular endothelial cell.
Type:
Grant
Filed:
March 11, 2021
Date of Patent:
May 30, 2023
Assignee:
POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Type:
Grant
Filed:
September 23, 2022
Date of Patent:
May 30, 2023
Assignee:
AbbVie Inc.
Inventors:
Ayman Allian, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Thomas B. Borchardt
Abstract: The invention relates to a process for producing ethylene glycol and/or ethylene carbonate, said process comprising contacting at least a portion of a recycle gas stream comprising an alkyl iodide impurity with a guard bed system positioned upstream of an ethylene oxide reactor to produce a treated recycle gas stream, wherein the guard bed system comprises silver on alumina; contacting a feed gas stream comprising ethylene, oxygen and at least a portion of the treated recycle gas stream with an epoxidation catalyst in the ethylene oxide reactor to produce an epoxidation reaction product comprising ethylene oxide; and contacting at least a portion of the epoxidation reaction product comprising ethylene oxide with an aqueous absorbent in the presence of an iodide-containing catalyst in an absorber to produce an aqueous product stream comprising ethylene carbonate and/or ethylene glycol and the recycle gas stream comprising the alkyl iodide impurity.
Type:
Grant
Filed:
December 6, 2018
Date of Patent:
May 23, 2023
Assignee:
SHELL USA, INC.
Inventors:
Roel Guillaume Hubertus Leonardus Bastings, Jesse Raymond Black, Vesna Bojovic, Wayne Errol Evans
Abstract: The present invention relates to a composition comprising a) at least one oil phase, b) at least one aqueous phase, c) at-least one emulsifier, wherein the at-least one emulsifier is any or combination of at-least one emulsifier agent, water with emulsification properties, oil with emulsification properties, and active ingredient with emulsification properties; and d) optionally, one or more biologically active ingredients. The present invention also relates to use of the composition for personal care, pet care, home care, deodorants, pesticides, moisturizers, disinfectants, cleansers, therapeutic devices, topical supplements and/or nutrition. The present invention also relates to a method for preparing such a composition.
Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.
Abstract: Disclosed herein is a ready-to-use liquid, injectable formulation comprising lidocaine and epinephrine. Also disclosed herein is a process for preparing a ready-to-use liquid formulation comprising lidocaine and epinephrine, as well as methods for using the ready-to-use liquid formulation.
Type:
Grant
Filed:
January 13, 2021
Date of Patent:
May 9, 2023
Assignee:
QUVA PHARMA, INC.
Inventors:
Travis A. Leeah, Jianping Chen, Lijie Zhao
Abstract: The subject invention provides catalytical compounds/complexes, compositions comprising such compound/complex, synthesis of the compounds/complexes, and methods of using such compounds/complexes as catalysts in, for example, RCM reactions. Specifically, the subject invention provides the synthesis of the first catalytically active V oxo alkylidene, VO(CHSiMe3)(PEt3)2Cl, which exhibits superior performance compared to other analogs.
Type:
Grant
Filed:
August 9, 2022
Date of Patent:
May 9, 2023
Assignee:
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES